Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts

Antisense-mediated exon skipping has made significant progress as a therapeutic platform in recent years, especially in the case of Duchenne muscular dystrophy (DMD). Despite FDA approval of eteplirsen–the first-ever antisense drug clinically marketed for DMD–exon skipping therapy still faces the si...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Joshua, Echigoya, Yusuke, Duddy, William, Saito, Takashi, Aoki, Yoshitsugu, Takeda, Shin’ichi, Yokota, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957359/
https://www.ncbi.nlm.nih.gov/pubmed/29771942
http://dx.doi.org/10.1371/journal.pone.0197084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957359/
https://www.ncbi.nlm.nih.gov/pubmed/29771942
http://dx.doi.org/10.1371/journal.pone.0197084

Ejemplares similares